![Alliance News](https://static.lse.co.uk/images/news-logos/alliance-news-logo.png)
UK shareholder meetings calendar - next 7 days
UK shareholder meetings calendar - next 7 days
Read moreThu, 25th Nov 2010 16:17
UK shareholder meetings calendar - next 7 days
Read more(Sharecast News) - Diagnostics and cancer therapies developer Avacta Group has entered into a non-exclusive distribution agreement with life science products company Calibre Scientific, it announced on Monday, for its 'AffiDX' SARS-CoV-2 antigen lateral flow test for professional use in the UK and the European Economic Area (EEA).
Read more(Sharecast News) - Diagnostics and cancer therapies developer Avacta Group has received notice of registration of its 'AffiDX' SARS-CoV-2 antigen lateral flow test in the European Union, allowing it to place the product on the market for professional use in all 27 countries of the EU.
Read moreAvacta Covid lateral flow test gets regulatory green light in EU
Read moreIN BRIEF: Avacta Covid lateral flow test gets regulatory green light
Read more(Sharecast News) - Diagnostics and cancer therapy developer Avacta Group announced on Monday that the Medicines and Healthcare products Regulatory Agency (MHRA) has confirmed registration of its 'AffiDX' SARS-CoV-2 antigen lateral flow test for Covid-19, allowing it to place the product on the market in the UK for professional use.
Read moreTRADING UPDATES: CML plans AIM move; IronRidge to demerge gold assets
Read more(Sharecast News) - Diagnostics and cancer therapies developer Avacta Group updated the market on its CE-mark submission for its 'AffiDX' SARS-CoV-2 antigen lateral flow test for professional use.
Read moreAvacta still waiting on response from UK regulator over Covid test
Read more(Sharecast News) - Cancer therapies and diagnostics developer Avacta Group responded to speculation around the CE-mark submission for its SARS-CoV-2 antigen lateral flow test on Friday.
Read moreIN BRIEF: Avacta to sell Covid-19 test in UK in "coming days"
Read moreAvacta sees Covid-19 tests driving earnings after reporting 2020 loss
Read more(Sharecast News) - Diagnostics and cancer therapies developer Avacta announced positive data from the clinical validation of its 'AffiDX' SARS-CoV-2 antigen lateral flow test on Tuesday.
Read moreIN BRIEF: Avacta's rapid Covid-19 test is 98% sensitive in trial
Read moreAIM WINNERS & LOSERS: Warpaint tops outlook; Avacta's Covid test works
Read more